Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND)

Visser, Eric P.; Postema, Ernst J.; Boerman, Otto C.; Visschers, Jeroen; Oyen, Wim J.G.; Corstens, F.H.M.

doi:10.1007/s00259-006-0226-z

Cited by 18 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Images consisted of summed counts collected in both windows. The scan speed was 8,6, and 4 cm/min at days 0, 2-4, and 5-7 after injection, respectively. The matrix size was 256 · 1,024, with a pixel size of 2.4 · 2.4 mm.…”

Section: Imaging and Pharmacokineticsmentioning

confidence: 99%

“…Residence times of the source organs and metastases were calculated using SPRIND, a software package for integrated data processing for internal dose assessment (6). Regions of interest for source organs and tumors were drawn on both anterior and posterior scintigraphic images.…”

Section: Dosimetrymentioning

confidence: 99%

“…Regions of interest for source organs and tumors were drawn on both anterior and posterior scintigraphic images. The counts within the regions of interest were corrected for attenuation and background contribution as described by Visser et al (6). The geometric mean was calculated, and the data were integrated over time using the trapezoid method.…”

Section: Dosimetrymentioning

confidence: 99%

“…In several studies, methods are defined to estimate the red marrow dose based on blood activity data or planar scintigrams (5)(6)(7)(8). Previous studies on the relationship between radiation dose estimates and myelotoxicity were variable (7,(9)(10)(11)(12)(13)(14)(15).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Dosimetric Analysis of ¹⁷⁷Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹In-cG250 Imaging

Stillebroer¹,

Zegers²,

Boerman³

et al. 2011

J Nucl Med

View full text Add to dashboard Cite

This study aimed to estimate the radiation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with 177 Lu-cG250. Serial planar scintigrams after injection of 111 In-cG250 or 177 Lu-cG250 in patients with metastasized renal cell carcinoma were analyzed quantitatively. The estimated radiation doses were correlated with observed hematologic toxicity. In addition, the accuracy of the predicted therapeutic absorbed doses, based on diagnostic 111 In-cG250 data, were determined. Methods: Twenty patients received a diagnostic tracer activity of 111 In-cG250 (185 MBq), followed by radioimmunotherapy with 177 Lu-cG250. The administered activity of 177 Lu-cG250 was escalated by entering 3 patients at each activity level starting at 1,110 MBq/m 2 , with increments of 370 MBq/m 2 . After each diagnostic and therapeutic administration, whole-body scintigraphic images and pharmacokinetic data were acquired. Hematologic toxicity was graded using the Common Toxicity Criteria, version 3.0. Diagnostic 111 In-cG250 data were used to simulate 177 Lu and 90 Y data by correcting for the difference in physical decay. Absorbed doses were calculated for the whole body, red marrow, organs, and tumor metastases for the therapeutic 177 Lu-cG250, simulated 177 Lu-cG250, and simulated 90 Y-cG250 data. Results: Observed hematologic toxicity, especially platelet toxicity, correlated significantly with the administered activity (r 5 0.85), whole-body absorbed dose (r 5 0.65), and red marrow dose (r 5 0.62 and 0.75). An inverse relationship between the mass and absorbed dose of the tumor lesions was observed. Calculated mean absorbed doses were similar for the simulated and measured 177 Lu-cG250 data. Absorbed doses (whole body and red marrow) based on the simulated 177 Lu-cG250 data correlated with the observed platelet toxicity (r 5 0.65 and 0.82). The tumor-to-red marrow dose ratio was higher for radioimmunotherapy with 177 Lu-cG250 than for radioimmunotherapy with 90 Y-cG250, indicating that 177 Lu has a wider therapeutic window for radioimmunotherapy with cG250 than 90 Y. Conclusion: In patients with metastasized renal cell carcinoma, hematologic toxicity after treatment with 177 Lu-cG250 can be predicted on the basis of administered activity and whole-body and red marrow-absorbed dose. Diagnostic 111 In-cG250 data can be used to accurately predict absorbed doses and myelotoxicity of radioimmunotherapy with 177 Lu-cG250. These estimations indicate that in these patients, higher radiation doses can be guided to the tumors with 177 LucG250 than with 90 Y-cG250.

show abstract

Section: Imaging and Pharmacokineticsmentioning

confidence: 99%

Section: Dosimetrymentioning

confidence: 99%

Section: Dosimetrymentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Dosimetric Analysis of ¹⁷⁷Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹In-cG250 Imaging

Stillebroer¹,

Zegers²,

Boerman³

et al. 2011

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Targeting of the radiolabeled monoclonal antibody in tumor tissue was determined by comparing the accumulation of the radiolabeled antibody in the RCC tumors with that in the contralateral kidney. In addition, the targeting of 111 In-bevacizumab was scored semiquantitatively, as described previously (19). In brief, regions of interest were drawn around tumors and the normal kidney on the planar images.…”

Section: Imagingmentioning

confidence: 99%

¹¹¹In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib

Desar¹,

Stillebroer²,

Oosterwijk³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)₂ antibody

Aarts

Boerman

Sharkey

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Antibody-based imaging agents are available commercially, but their success has been limited, mainly because of low contrast and the emergence of 2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) scanning. In pretargeting, administration of the radionuclide is separated from the antibody, thereby enhancing image contrast and allowing detection at earlier time points after injection. METHODS: The authors conducted an open-label, single-arm trial that assessed a pretargeting procedure in which an anticarcinoembryonic antigen x (anti-CEA x) anti-diethylenetriaminepentaacetic acid (anti-DTPA)-indum (In) antibody was used in combination with a 111 In-labeled di-DTPA peptide for the diagnostic imaging of CEA-expressing colorectal cancer. Three patients received the 111 In peptide alone to investigate tumor targeting, organ distribution, and clearance of the peptide. Thereafter, 11 patients received the bispecific antibody (bsAb) (5 mg) to pretarget the tumor. After 3 to 5 days, patients were injected with 185 megabecquerels of 111 In-labeled peptide to assess the optimal interval for best image quality. RESULTS: Fourteen patients with primary colorectal cancer were enrolled. One of 3 patients who received 111 In peptide alone had low-level tumor uptake. In 9 of 11 other patients, tumors were observed. In 1 patient, FDG-PET-positive lymph nodes were observed clearly with pretargeted immunoscintigraphy. Peptide pharmacokinetics revealed enhanced circulating levels of 111 In-labeled peptide in patients in the 3-day interval cohort compared with the other cohorts. Tumor-to-background ratios ranged from 3.5 to 6.4 in the 3-day interval group, from 5.1 to 14.2 in the 4-day interval group, and from 3.5 to 3.9 in the 5-day interval group. The best images were acquired with a 4-day interval at 24 hours after injection of the radiolabeled peptide. Grade 1 adverse events were observed in 2 patients. CONCLUSIONS: Imaging of colorectal cancer using a 2-step, pretargeting system produced the best imaging results 24 hours after peptide administration using a 4-day interval between injection of the bsAb and the peptide. Cancer 2010;116(4 suppl):1111-7.

show abstract

Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND)

Abstract: SPRIND is an easy-to-use software package for radiation dose assessment studies. It has made these studies less time consuming and less error prone.

Cited by 18 publications

References 8 publications

Dosimetric Analysis of ¹⁷⁷Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹In-cG250 Imaging

Dosimetric Analysis of ¹⁷⁷Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹In-cG250 Imaging

¹¹¹In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib

Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)₂ antibody

Contact Info

Product

Resources

About

Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND)

Abstract: SPRIND is an easy-to-use software package for radiation dose assessment studies. It has made these studies less time consuming and less error prone.

Cited by 18 publications

References 8 publications

Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging

Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging

111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib

Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)2 antibody

Contact Info

Product

Resources

About

Dosimetric Analysis of ¹⁷⁷Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹In-cG250 Imaging

Dosimetric Analysis of ¹⁷⁷Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹In-cG250 Imaging

¹¹¹In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib

Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)₂ antibody